CN102824441A - Method for preparing Fructus Aurantii ingredients having anti-liquid-accumulation activity, and use - Google Patents
Method for preparing Fructus Aurantii ingredients having anti-liquid-accumulation activity, and use Download PDFInfo
- Publication number
- CN102824441A CN102824441A CN2012103022906A CN201210302290A CN102824441A CN 102824441 A CN102824441 A CN 102824441A CN 2012103022906 A CN2012103022906 A CN 2012103022906A CN 201210302290 A CN201210302290 A CN 201210302290A CN 102824441 A CN102824441 A CN 102824441A
- Authority
- CN
- China
- Prior art keywords
- fructus aurantii
- ethanol
- ethanol elution
- neohesperidin
- naringin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a method for preparing Fructus Aurantii ingredients having anti-liquid-accumulation activity and a use, concretely to a Fructus Aurantii extractive containing 20 to 42 % of naringin and 20 to 48 % of neohesperidin. The Fructus Aurantii extractive is prepared by the following method comprising smashing the Fructus Aurantii medicinal materials, adding 20 to 90 % ethanol, extracting for 1 to 3 times under reflux by heating, combining filtrates to get extracting solutions, condensing the extracting solutions to get extractum, mixing the extractum with macroporous resin, purifying with a macroporous resin column, collecting 60 to 80 % ethanol eluates, condensing, purifying with a polyamide column, collecting 20 % ethanol eluates, condensing and drying to get the Fructus Aurantii ingredients. The Fructus Aurantii extractive can be used for preparing medicaments for treating non-alcoholic fatty liver.
Description
Technical field
The invention belongs to the Chemistry for Chinese Traditional Medicine field, relate in particular to a kind of active component that from Fructus Aurantii, extracts and preparation method thereof, and the application of this component in preparation non-alcoholic fatty liver disease medicine.
Background technology
Hepatic injury is the complex process that is caused and had multiple factor to participate in by Different types of etiopathogenises.The hepatic disease that hepatic injury causes has become commonly encountered diseases, frequently-occurring disease, the liver failure of its initiation that even more serious is and hepatic encephalopathy etc., and the M & M height is greatly threatening human health.Several factors can cause hepatic injury.Non-alcoholic fatty liver disease (nonalcoholic fatty liver disease; NAFLD); Claim non-alcoholic fatty liver disease (nonalcoholic fatty liver again; NAFL), be a kind of no excessive history of drinking history, storing up with fat with the hepatic parenchymal cells steatosis is the clinical pathology syndrome of characteristic.Non-alcoholic fatty liver disease comprises a series of hepatic disease, from single steatosis in various degree steatosis associating necrosis and fibrosis.The unusual accumulation of hepatocyte inner lipid then is the main factor that the fatty liver disease takes place.Oleic acid is one of fatty acid the abundantest in the human body; It participates in forming the triglyceride in the liver and promoting the formation that fat drips; It is a kind of lipid accumulation cell model commonly used that oleic acid is induced the HepG2 accumulation of fat, can be used for estimating the lipotropism matter cumulative function of medicine.
At present, the non-alcoholic fatty liver disease Therapeutic Method has a lot, and certain curative effect is all arranged, but also exists tangible deficiency.At first, Western medicine has bigger toxic and side effects, and curative effect and imprecise.And on the other hand; Experiment and clinical research confirmation; Chinese medicine demonstrates good curative effect at aspects such as improving liver function, antioxidation, microcirculation improvement, adjusting immunologic function and anti-hepatic fibrosis; Safe, reliable and effective, further demonstrate the reasonability of differentiation of tcm, highlighted Chinese medicine and claimed the good prospect aspect the non-alcoholic fatty liver disease in treatment.
Fructus Aurantii is to be the rutaceae Citrus aurantium Linn.
Citrus aurantiumL. and the dry immature fruit of variety, its nature and flavor are bitter, sour, and cold nature cures mainly septum pectorale feeling of fullness, distending pain over the hypochondrium, accumulation of food in the stomach and intes tine due to indigestion, distension and fullness in the abdomen etc.Modern pharmacology research shows that Fructus Aurantii is two-way function to gastrointestinal smooth muscle, both can excited gastrointestinal smooth muscle, can reduce the gastrointestinal smooth muscular tension again; Can prevent rat pylorus ligation ulcer, have the effect of remarkable minimizing gastric secretion and reduction pepsin activity; Have the coronary flow of increasing and kidney blood flow blood in addition, reduce effects such as myocardial oxygen consumption.But whether the Fructus Aurantii component has the activity that suppresses the hepatocyte lipid accumulation it be unclear that.
Summary of the invention
The purpose of this invention is to provide a kind of Fructus Aurantii active component, this active component mainly contains the A naringin, two kinds of chemical compounds of B neohesperidin, and wherein the content of A is 20%-42%, the content of B is 20%-48%.
The content of preferred A is 30 ~ 40%, and the content of B is 30 ~ 40%.
Another object of the present invention provides the method for preparing of this Fructus Aurantii active component, realizes through following steps: with the ethanol that adds 20% ~ 90% after the Fructus Aurantii pulverizing medicinal materials, and reflux 0.8 ~ 1.2 hour; Extract 1 ~ 3 time, merging filtrate gets extracting solution, and extracting solution is condensed into extractum; And itself and macroporous resin mixed appearance, and with macroporous resin column it is carried out purification, collect 70% ethanol elution; Concentrate after collect 20% ethanol elution behind the polyamide column purification, behind concentrate drying, obtain active component.
A further object of the present invention provides the application of this Fructus Aurantii active component in preparation non-alcoholic fatty liver disease medicine.
Particularly:
First aspect present invention provides a kind of Fructus Aurantii extract (also can be described as the Fructus Aurantii active component in the present invention), wherein contain naringin and neohesperidin, and wherein the content of naringin is 20%-42%, and the content of neohesperidin is 20%-48%.In one embodiment, the content of naringin is 30 ~ 40%, and the content of neohesperidin is 30 ~ 40%.In one embodiment, the content of naringin is 25 ~ 35%, and the content of neohesperidin is 20 ~ 30%.
First aspect present invention also provides a kind of Fructus Aurantii extract (also can be described as the Fructus Aurantii active component in the present invention), wherein contains naringin and neohesperidin, and the naringin and the content that wherein contain the 20-42 weight portion are the neohesperidin of 20-48 weight portion.In one embodiment, the naringin and the content that contain the 30-40 weight portion in this Fructus Aurantii extract are the neohesperidin of 30-40 weight portion.In one embodiment, the naringin and the content that contain the 25-35 weight portion in this Fructus Aurantii extract are the neohesperidin of 20-30 weight portion.
According to the Fructus Aurantii extract of first aspect present invention, it prepares through following method: with the ethanol that adds 20% ~ 90% (for example 60-80%, for example 65-75%) after the Fructus Aurantii pulverizing medicinal materials, heating and refluxing extraction 1 ~ 3 time; Merging filtrate gets extracting solution, and extracting solution is condensed into extractum, and itself and macroporous resin are mixed appearance, with macroporous resin column it is carried out purification; Collect 60 ~ 80% ethanol elution, concentrate, through the polyamide column purification; Collect 20% ethanol elution,, promptly get through concentrate drying.
Fructus Aurantii extract according to first aspect present invention; It prepares through following method: the 1500g Fructus Aurantii is added 4200ml 70% ethanol extraction 2h, add 3500ml 70% ethanol extraction 1.5h again, add 2800ml 70% ethanol extraction 1h at last; Merge three times extracting solution, concentrate behind the sucking filtration.Concentrated solution is crossed macroporous resin (D101), and earlier with behind the water elution, reuse 20% ethanol elution is at last with 70% ethanol elution.Collect 70% ethanol elution, be concentrated into about 150ml, sucking filtration is crossed polyamide column, with 4 column volumes of 20% ethanol elution, collects eluent; 5 column volumes of reuse 40% ethanol elution divide 10 sections to collect eluent, every section 500ml.20% ethanol elution section is revolved steaming, weigh after the lyophilization, promptly get.
Second aspect present invention provides the method for preparing Fructus Aurantii extract, and it may further comprise the steps: with the ethanol that adds 20% ~ 90% (for example 60-80%, for example 65-75%) after the Fructus Aurantii pulverizing medicinal materials, heating and refluxing extraction 1 ~ 3 time; Merging filtrate gets extracting solution, and extracting solution is condensed into extractum, and itself and macroporous resin are mixed appearance, with macroporous resin column it is carried out purification; Collect 60 ~ 80% ethanol elution, concentrate, through the polyamide column purification; Collect 20% ethanol elution,, promptly get through concentrate drying.
According to the method for second aspect present invention, it may further comprise the steps: the 1500g Fructus Aurantii is added 4200ml 70% ethanol extraction 2h, add 3500ml 70% ethanol extraction 1.5h again, add 2800ml 70% ethanol extraction 1h at last, merge three times extracting solution, concentrate behind the sucking filtration.Concentrated solution is crossed macroporous resin (D101), and earlier with behind the water elution, reuse 20% ethanol elution is at last with 70% ethanol elution.Collect 70% ethanol elution, be concentrated into about 150ml, sucking filtration is crossed polyamide column, with 4 column volumes of 20% ethanol elution, collects eluent; 5 column volumes of reuse 40% ethanol elution divide 10 sections to collect eluent, every section 500ml.20% ethanol elution section is revolved steaming, weigh after the lyophilization, promptly get.
According to the method for second aspect present invention, contain naringin and neohesperidin in its gained Fructus Aurantii extract, and wherein the content of naringin is 20%-42%, the content of neohesperidin is 20%-48%.In one embodiment, the content of naringin is 30 ~ 40%, and the content of neohesperidin is 30 ~ 40%.In one embodiment, the content of naringin is 25 ~ 35%, and the content of neohesperidin is 20 ~ 30%.
According to the method for second aspect present invention, contain naringin and neohesperidin in its gained Fructus Aurantii extract, and the naringin and the content that wherein contain the 20-42 weight portion are the neohesperidin of 20-48 weight portion.In one embodiment, the naringin and the content that contain the 30-40 weight portion in this Fructus Aurantii extract are the neohesperidin of 30-40 weight portion.In one embodiment, the naringin and the content that contain the 25-35 weight portion in this Fructus Aurantii extract are the neohesperidin of 20-30 weight portion.
Third aspect present invention provides the application of Fructus Aurantii extract in preparation non-alcoholic fatty liver disease medicine of first aspect present invention.
Fourth aspect present invention provides a kind of pharmaceutical composition, comprising Fructus Aurantii extract and the pharmaceutically acceptable carrier or the excipient of first aspect present invention.
Fructus Aurantii active component of the present invention can be used as active site, adds drug excipient or the carrier accepted on the pharmaceutics, processes preparation according to the method for putting down in writing on the pharmaceutics.
The dosage form of said medicine comprises liquid preparation, solid preparation, capsule, soft gelatin capsule.Comprise injection, drip liquid, injectable powder, granule, tablet, electuary, powder, oral liquid, sugar coated tablet, film coated tablet, enteric coated tablet, capsule, hard capsule, soft capsule, suck agent, granule, pill, unguentum, sublimed preparation, spray, drop pill, disintegrating agent, oral cavity disintegration tablet, micropill etc.
In the present invention, term " Fructus Aurantii component " can be described as " Fructus Aurantii extract " perhaps " Fructus Aurantii active component " etc., and these terms can exchange use.
Beneficial effect of the present invention is:
1. extraction and separation process of the present invention is simple, can obtain active component rapidly and accurately.
2. Fructus Aurantii active component chemical constituent provided by the invention is simply clear and definite, on pharmacological research, is easier to illustrate its mechanism of action, is easier to the quality control of medicine aborning.
3. the present invention induces HepG at oleic acid first
2On the accumulation of fat model, estimate Fructus Aurantii extract antagonism lipid accumulation effect for reducing fat, obtained pharmacologically active preferably.
Description of drawings
Fig. 1 is the HPLC analysis chart of Fructus Aurantii extract of the present invention.
Fig. 2 has shown that the variable concentrations Fructus Aurantii extract is to the cumulative influence of the inductive HepG2 cytolipin of 500uM oleic acid.
Fig. 3 has described variable concentrations naringin and neohesperidin to the cumulative influence of the inductive HepG2 cytolipin of 500uM oleic acid.
The specific embodiment
The present invention combines accompanying drawing and following embodiment further explain flesh and blood of the present invention, and this embodiment only is used to the present invention is described and is not limitation of the present invention.
The preparation of embodiment one Fructus Aurantii active component
The 1500g Fructus Aurantii is added 4200ml 70% ethanol extraction 2h, add 3500ml 70% ethanol extraction 1.5h again, add 2800ml 70% ethanol extraction 1h at last, merge three times extracting solution, concentrate behind the sucking filtration.Concentrated solution is crossed macroporous resin (D101), and earlier with behind the water elution, reuse 20% ethanol elution is at last with 70% ethanol elution.Collect 70% ethanol elution, be concentrated into about 150ml, sucking filtration is crossed polyamide column, with 4 column volumes of 20% ethanol elution, collects eluent; 5 column volumes of reuse 40% ethanol elution divide 10 sections to collect eluent, every section 500ml.20% ethanol elution section is revolved steaming, weigh after the lyophilization, get Fructus Aurantii component 47.5608g.It is used for the biological test of hereinafter.
The analysis of embodiment two Fructus Aurantii active components
Chromatographic conditionAgilent 1100 type high performance liquid chromatographs, chromatographic column is SB-C
18Chromatographic column; With acetonitrile-water (20:80) (regulating pH value to 3 with phosphoric acid) is mobile phase; The detection wavelength is 283nm; The liquid chromatograph flow velocity is 1ml/min, sample size 10 μ l.
The preparation of need testing solutionThese article of taking by weighing in volumetric flask, are diluted to 2mg/ml with dissolve with methanol solution, shake up, and promptly get.
Assay methodThe accurate need testing solution of drawing injects chromatograph of liquid, measures according to chromatographiccondition, promptly gets.
Analysis resultThe efficient liquid phase chromatographic analysis spectrogram of Fructus Aurantii active component is seen Fig. 1, and the chromatographic peak that retention time is respectively 16min and 11.5min among two figure is respectively A, two chemical compounds of B.Use identical chromatographic conditions, analyzed naringin and neohesperidin standard substance, find that compd A is identical with the naringin retention time, find that chemical compound is identical with the neohesperidin retention time, so authenticating compound A and B are respectively naringin and neohesperidin.Assay is the result show, naringin and neohesperidin content in extract is respectively 31.2% and 25.8%.Unexpectedly find; In embodiment 1,, perhaps be higher than 80% ethanol extraction with concentration if be lower than 60% ethanol extraction with concentration; The macroporous resin of perhaps using other model instead carries out eluting, and compd A and B acquisition amount the acquisition amount than embodiment 1 respectively are low more than 33% and 30%.When preparing with 65-75% ethanol and with the D101 macroporous resin, compd A and B acquisition amount be embodiment 1 the acquisition amount 93% ~ 115%, and the content of compd A is between 25-35% in the extract, the content of compd B is between 20-30%.
Embodiment three Fructus Aurantii active component preparations
Get the Fructus Aurantii active component 0.5g and 10.5g Polyethylene Glycol-6000 mix homogeneously of embodiment 1 gained, heating and melting moves in the drop pill drip irrigation behind the change material, and in ℃ liquid paraffin of medicine liquid droplet to 6 ~ 8, oil removing makes 400 of drop pill.
Embodiment four Fructus Aurantii active component preparations
Get the Fructus Aurantii active component 0.5g of embodiment 1 gained, wear into fine powder, with about 1/3 starch mixing; Add the starch slurry mixing and process soft material, 16 mesh sieves are granulated, 70 ℃ of dryings; Dry granular is crossed 14 mesh sieve granulate, adds remaining starch (in advance 100-105 ℃ of drying) and the Pulvis Talci (light liquid petrolatum is sprayed on mixing in the Pulvis Talci) that is adsorbed with liquid Paraffin, again through 14 mesh sieves; Tabletting promptly gets the evaluation of embodiment five Fructus Aurantii active component lipotropism matter cumulated activities
Dissolve component to be measured in DMSO, get 50 mgmL-1 storing solutions, the final concentration of hatching with cell is 50 μ gmL-1, at the inductive HepG of oleic acid
2It suppresses the lipid accumulation activity hepatocyte model evaluation.
The density of well-grown HepG2 cell with every hole 200,000 cells is inoculated in the 24 porocyte culture plates every hole culture fluid 1ml.Treat (about 24 hours) behind the cell attachment; Divide matched group and administration group to handle, parallel three experiments add 0.5mM oleic acid in the matched group; Add 0.5mM oleic acid and 75,100,150,200 ug/ml embodiment, 1 gained Fructus Aurantii extract in the administration group, in 37 ℃, 5%CO
2Condition under cultivate 24h after, discard every hole supernatant, enzymatic assays triglyceride, total cholesterol level.Assay method is that 24 porocyte culture plates are washed twice with pre-cooling PBS500ul; Every hole adds 200ul cell pyrolysis liquid cracking 30min; Get the total liquid of cracking in the 1.5ml centrifuge tube, centrifugal 10min (12000rpm, 4 ℃); Getting supernatant 80ul respectively adds the agent of 100ul triglyceride enzyme and surveys every hole triglyceride (TG) content; 80ul adds the agent of 100ul cholesterol enzyme and surveys every hole cholesterol (TC) content, and 10ul surveys protein content with the BCA method, calculates proteic TG of every hole unit and TC content (ug/mg protein).
The result shows that embodiment 1 gained Fructus Aurantii extract is at 50ug/ml, and 100ug/ml has obvious suppression oleic acid to induce the cumulative effect of triglyceride in the HepG2 cell, and is dose-effect relationship under the 200ug/ml concentration.Specifically see Fig. 2, it has described the variable concentrations Fructus Aurantii extract to the cumulative influence of the inductive HepG2 cytolipin of 500uM oleic acid, and wherein vertical coordinate representes that the % " Fructus Aurantii flavone " that contrasts is a Fructus Aurantii extract of the present invention.
The lipotropism matter cumulated activity of main component is estimated in the embodiment six Fructus Aurantii components
Main component naringin and neohesperidin in the Fructus Aurantii component are mixed with 10,25,50,100,150,200 μ molL
-1Solution is at the inductive HepG of oleic acid
2It suppresses the lipid accumulation activity hepatocyte model evaluation.The result shows that neohesperidin is at concentration 100u μ molL
-1There is obvious suppression oleic acid to induce HepG when above
2The cumulative effect of cell TG and TC, and be certain concentration dependent; Naringin is 200 μ molL in concentration
-1The time have obvious suppression oleic acid to induce HepG2 cell TG and the cumulative effect of TC.Specifically see Fig. 3, it has described variable concentrations naringin and neohesperidin to the cumulative influence of the inductive HepG2 cytolipin of 500uM oleic acid, and wherein vertical coordinate is represented the % that contrasts.
Claims (10)
1. a Fructus Aurantii extract wherein contains naringin and neohesperidin, and wherein the content of naringin is 20%-42%, and the content of neohesperidin is 20%-48%.
2. a Fructus Aurantii extract wherein contains naringin and neohesperidin, and the naringin and the content that wherein contain the 20-42 weight portion are the neohesperidin of 20-48 weight portion.
3. according to the Fructus Aurantii extract of claim 1 or 2, it prepares through following method: with the ethanol that adds 20% ~ 90% after the Fructus Aurantii pulverizing medicinal materials, and heating and refluxing extraction 1 ~ 3 time, merging filtrate gets extracting solution; Extracting solution is condensed into extractum, and itself and macroporous resin are mixed appearance, it is carried out purification with macroporous resin column; Collect 60 ~ 80% ethanol elution, concentrate, through the polyamide column purification; Collect 20% ethanol elution,, promptly get through concentrate drying.
4. according to the Fructus Aurantii extract of claim 1 or 2; It prepares through following method: the 1500g Fructus Aurantii is added 4200ml 70% ethanol extraction 2h, add 3500ml 70% ethanol extraction 1.5h again, add 2800ml 70% ethanol extraction 1h at last; Merge three times extracting solution, concentrate behind the sucking filtration; Concentrated solution is crossed macroporous resin (D101), and earlier with behind the water elution, reuse 20% ethanol elution is at last with 70% ethanol elution; Collect 70% ethanol elution, be concentrated into about 150ml, sucking filtration is crossed polyamide column, with 4 column volumes of 20% ethanol elution, collects eluent; 5 column volumes of reuse 40% ethanol elution divide 10 sections to collect eluent, every section 500ml; 20% ethanol elution section is revolved steaming, weigh after the lyophilization, promptly get.
5. prepare the method for Fructus Aurantii extract, it may further comprise the steps: with the ethanol that adds 20% ~ 90% after the Fructus Aurantii pulverizing medicinal materials, and heating and refluxing extraction 1 ~ 3 time, merging filtrate gets extracting solution; Extracting solution is condensed into extractum, and itself and macroporous resin are mixed appearance, it is carried out purification with macroporous resin column; Collect 60 ~ 80% ethanol elution, concentrate, through the polyamide column purification; Collect 20% ethanol elution,, promptly get through concentrate drying.
6. according to the method for claim 5, it may further comprise the steps: the 1500g Fructus Aurantii is added 4200ml 70% ethanol extraction 2h, add 3500ml 70% ethanol extraction 1.5h again, add 2800ml 70% ethanol extraction 1h at last, merge three times extracting solution, concentrate behind the sucking filtration; Concentrated solution is crossed macroporous resin, and earlier with behind the water elution, reuse 20% ethanol elution is at last with 70% ethanol elution; Collect 70% ethanol elution, be concentrated into about 150ml, sucking filtration is crossed polyamide column, with 4 column volumes of 20% ethanol elution, collects eluent; 5 column volumes of reuse 40% ethanol elution divide 10 sections to collect eluent, every section 500ml; 20% ethanol elution section is revolved steaming, weigh after the lyophilization, promptly get.
7. according to the method for claim 5 or 6, contain naringin and neohesperidin in its gained Fructus Aurantii extract, and wherein the content of naringin is 20%-42%, the content of neohesperidin is 20%-48%.
8. according to the method for claim 5 or 6, contain naringin and neohesperidin in its gained Fructus Aurantii extract, and the naringin and the content that wherein contain the 20-42 weight portion are the neohesperidin of 20-48 weight portion.
9. each the application of Fructus Aurantii extract in preparation non-alcoholic fatty liver disease medicine of claim 1-8.
10. pharmaceutical composition is comprising Fructus Aurantii extract and the pharmaceutically acceptable carrier or the excipient of first aspect present invention.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210302290.6A CN102824441B (en) | 2012-08-23 | 2012-08-23 | Method for preparing Fructus Aurantii ingredients having anti-liquid-accumulation activity, and use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210302290.6A CN102824441B (en) | 2012-08-23 | 2012-08-23 | Method for preparing Fructus Aurantii ingredients having anti-liquid-accumulation activity, and use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102824441A true CN102824441A (en) | 2012-12-19 |
| CN102824441B CN102824441B (en) | 2014-06-11 |
Family
ID=47327887
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210302290.6A Active CN102824441B (en) | 2012-08-23 | 2012-08-23 | Method for preparing Fructus Aurantii ingredients having anti-liquid-accumulation activity, and use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102824441B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110882319A (en) * | 2019-11-19 | 2020-03-17 | 衢州市人民医院 | Application of thoroughfare bitter orange, thoroughfare bitter orange extract and products containing thoroughfare bitter orange extract in preventing and/or treating metabolic liver diseases |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2605971A (en) * | 2021-04-19 | 2022-10-26 | Citrox Biosciences Ltd | Nutritional supplement and uses |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100486586C (en) * | 2004-09-17 | 2009-05-13 | 王英锋 | Imature bitter orange total flavone and its preparing method for its preparation and quality control method |
| CN101062165B (en) * | 2007-06-18 | 2010-06-16 | 石任兵 | Citrus aurantium total flavone extract and the preparing method thereof |
-
2012
- 2012-08-23 CN CN201210302290.6A patent/CN102824441B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100486586C (en) * | 2004-09-17 | 2009-05-13 | 王英锋 | Imature bitter orange total flavone and its preparing method for its preparation and quality control method |
| CN101062165B (en) * | 2007-06-18 | 2010-06-16 | 石任兵 | Citrus aurantium total flavone extract and the preparing method thereof |
Non-Patent Citations (3)
| Title |
|---|
| 《浙江大学学报（医学版）》 20110125 栾连军等 枳壳总黄酮的多指标质量控制 17-18 1-8 第40卷, 第1期 * |
| 栾连军等: "枳壳总黄酮的多指标质量控制", 《浙江大学学报（医学版）》, vol. 40, no. 1, 25 January 2011 (2011-01-25), pages 17 - 18 * |
| 舒尊鹏等: "中药枳壳化学成分及药理作用研究", 《科技创新与应用》, 15 July 2012 (2012-07-15), pages 8 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110882319A (en) * | 2019-11-19 | 2020-03-17 | 衢州市人民医院 | Application of thoroughfare bitter orange, thoroughfare bitter orange extract and products containing thoroughfare bitter orange extract in preventing and/or treating metabolic liver diseases |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102824441B (en) | 2014-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100366280C (en) | Medicinal composition for treating hypertension, its preparation method and use | |
| CN102133222B (en) | Compound Chinese medicine extract preventing arteriosclerosis and preparation method thereof | |
| CN101590101A (en) | A kind of prescription and preparation technology who treats type and complication thereof | |
| CN104706855A (en) | Preparation methods and application of Jichuan decoction traditional Chinese medicine extract | |
| CN102160876B (en) | Plant extract composition for preventing and treating arteriosclerosis and preparation method thereof | |
| CN102670642A (en) | Traditional Chinese compound medicament for treating fatty liver disease | |
| CN102824441B (en) | Method for preparing Fructus Aurantii ingredients having anti-liquid-accumulation activity, and use | |
| CN101474275B (en) | Preparation method and application of Chinese medicine extract for 'prescription for treating diarrhoea with abdominal pain' | |
| CN100566720C (en) | A kind of Chinese medicine active ingredient composition for the treatment of cardiovascular and cerebrovascular disease and uses thereof | |
| CN102824382A (en) | Method for preparing Ligusticum wallichii lactone extract having anti-liquid-accumulation activity, and use | |
| CN1931233B (en) | Medicine composition of red sage and epimedium for treating cardiac and cerebral vascular diseases | |
| CN101618131A (en) | Chinese medicinal compound preparation for treating coronary heart disease and angina | |
| CN101612184B (en) | Multiradiate fleabane extract, composition containing same, preparation method and application thereof | |
| CN104116753B (en) | The application of aucubin in preparation treatment idiopathic pulmonary fibrosis medicine | |
| CN106361811A (en) | Tongmai pharmaceutical composition and preparation method thereof | |
| CN102552325A (en) | Bear gall extract, preparation method thereof and application thereof to preparation of fatty liver treatment medicament | |
| CN101766683B (en) | Salvia dispersible tablet and application thereof | |
| CN1839931B (en) | Medicine composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN107693576A (en) | A kind of Chinese medicine composition for being used to treat coronary heart disease | |
| CN107029124A (en) | It is a kind of to be used to treat Chinese medicine composition of essential hypertension and preparation method thereof | |
| CN103520314B (en) | A kind of antiatheroscloresis medicine compounds and preparation method thereof | |
| CN101850035A (en) | Tibetan medicine-containing composition with anti-hepatic fibrosis function, preparation method thereof and application thereof in preparing anti-hepatic fibrosis medicines | |
| CN102670785B (en) | Preparation method of conventional Chinese medicine composition for treating primary hypertension | |
| CN101084965A (en) | Safflower compound preparation and its preparation technology | |
| CN102475785B (en) | Preparation method of Chinese medicinal composition for treating essential hypertension |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |